Global $6+ Billion CAR-T Therapy Market Opportunities and Strategies to 2030 – ResearchAndMarkets.com

Global $6+ Billion CAR-T Therapy Market Opportunities and Strategies to 2030 – ResearchAndMarkets.com




Global $6+ Billion CAR-T Therapy Market Opportunities and Strategies to 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CAR-T Therapy Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery” report has been added to ResearchAndMarkets.com’s offering.

The global CAR-T therapy market reached a value of nearly $734.0 million in 2019. The market is expected to grow from $734.0 million in 2019 to $2,250 million in 2023 at a rate of 32.3%. The growth is mainly due to an increased prevalence of cancer and increased awareness about the therapy. The market is expected to stabilize and reach $3,150 million in 2025 and $6,100 million in 2030.

The CAR-T therapy market consists of sales of CAR-T therapy products and related services by entities (organizations, sole traders and partnerships) that develop chimeric antigen receptor (CAR) T-cell therapies to treat all types of cancers. This industry includes establishments that are involved in the research and development to introduce new targeted cell therapies for treating different blood related cancers.

Growth in the historic period resulted from increases in healthcare expenditure, increase in pharmaceutical R&D expenditure and advances in drug discovery. This growth was restricted by low rate of drug approvals, challenges due to regulatory changes and limited number of treatment centers.

Going forward, increase in blood cancer incidence rate, rise in healthcare expenditure, strong pipeline of drugs and rising focus on car-t therapy are expected to drive the market. High costs of therapy, reimbursement challenges, adverse events, complex manufacturing and supply chain and covid-19 impacting drug trails, and reduction in free trade are major factors that could hinder the growth of the CAR-T therapy market in the future.

The CAR-T therapy market is segmented by target antigen into CD19, CD22, BCMA and others. The CD19 was the largest segment of the CAR-T therapy market by target antigen, accounting for 100% of the total market in 2019. Going forward, CD19 segment is expected to be the fastest growing segment in the CAR-T therapy market, at a CAGR of 25.3%.

The CAR-T therapy market is also segmented by application into acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma and others. The diffuse large B-cell lymphoma was the largest segment of the CAR-T therapy market by application, accounting for 56.1% of the total market in 2019. Going forward, the others segment is expected to be the fastest growing segment in the CAR-T therapy market, at a CAGR of 29.3%.

North America was the largest region in the global CAR-T therapy market, accounting for 60.3% of the total in 2019. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the CAR-T therapy market will be Asia Pacific and Western Europe, where growth will be at CAGRs of 85.1% and 32.4% respectively.

The CAR-T therapy market is particularly prone to disruption from the coronavirus outbreak, as patients with cancer are more susceptible to viral infections, especially after chemotherapy, stem cell transplants, or surgeries. COVID-19 has caused clinical trial delays for CAR-T therapy drugs. Due to worldwide lockdown, production is also being halted which is causing supply chain issues.

The CAR-T therapy market is concentrated, with a small number of large of large players in the market. Major players in the market include Novartis AG and Gilhead Pharmaceuticals.

The top opportunities in the CAR-T therapy market segmented by target antigen will arise in the CD19 segment, which will gain $1,077.3 million of global annual sales by 2023. The top opportunities in the CAR-T therapy market segmented by application will arise in the diffuse large B-cell lymphoma segment, which will gain $738.5 million of global annual sales by 2023. The CAR-T therapy market size will gain the most in the USA at $744.9 million.

Market-trend-based strategies for the CAR-T therapy market include focus efforts towards investing in the R&D for creating remodeled CAR-T therapy to avoid neurological side-effects, creating off-the-shelf allogeneic CAR-T therapy for advanced cancer treatment, manufacturing next-generation CAR T cells for improved treatment of high-grade glioma, investing in AI and machine learning solutions to optimize future CAR-T therapy, carrying out strategic collaborations to boost innovations, collaborating or acquiring competitor companies to expand CAR-T therapy portfolio, and investing in the CAR-T therapy to make it more effective. Player-adopted strategies in the CAR-T therapy market include expansion through mergers and acquisitions, and strategic partnerships with technology companies.

To take advantage of the opportunities, the publisher recommends the CAR-T therapy companies should consider collaborating or acquiring competitor companies, invest in machine learning and artificial intelligence, next-generation car-t cells, competitive pricing, expanding in emerging markets, set up authorized distributors and sales representatives, leverage e-commerce to maximize reach and revenues, increasing adoption of internet, attending business events, targeting community oncologists/hematologists, and collaboration with treatment centers.

Companies Mentioned

  • Adaptimmune
  • Aeon Therapeutics
  • Astellas Pharma
  • AstraZeneca Holding GmbH
  • Autolus Therapeutics
  • Biocon
  • BioNTech
  • CARsgen Therapeutics
  • Celegne
  • Cellectis
  • Celyad
  • Crescendo Biologics
  • Daiichi Sankyo
  • Eli Lilly and Company
  • GammaDelta Therapeutics
  • Gilead Sciences
  • Gracell Biotechnology Ltd
  • Hebei Senlang Biotech
  • Immatics
  • Innovative Cellular Therapeutics Cellular Biomedicine Group
  • Japan Tissue Engineering
  • Johnson & Johnson Private Limited
  • MSD Laboratories India LLC
  • Nipro Corporation
  • Novartis AG
  • Ono Pharmaceutical
  • Otsuka Pharmaceutical
  • PersonGen Biomedicine
  • Takeda Pharmaceutical Company

For more information about this report visit https://www.researchandmarkets.com/r/jrdli0

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900